AR085538A1 - Vacunas para la tuberculosis (tb) basadas en el direccionamiento hacia las celulas dendriticas (dc) - Google Patents
Vacunas para la tuberculosis (tb) basadas en el direccionamiento hacia las celulas dendriticas (dc)Info
- Publication number
- AR085538A1 AR085538A1 ARP120100964A ARP120100964A AR085538A1 AR 085538 A1 AR085538 A1 AR 085538A1 AR P120100964 A ARP120100964 A AR P120100964A AR P120100964 A ARP120100964 A AR P120100964A AR 085538 A1 AR085538 A1 AR 085538A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccines
- tuberculosis
- antigens
- addressing
- dendritic cells
- Prior art date
Links
- 201000008827 tuberculosis Diseases 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 101150106931 IFNG gene Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000001268 conjugating effect Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/464817—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Composiciones y métodos que comprenden conjugados de anticuerpos monoclonales de alta afinidad contra diversos receptores de las DC. Se trata de proteínas de fusión con antígenos dirigidos a las DC que se preparan mediante la conjugación de diversas proteínas antigénicas de M. tuberculosis con anticuerpos monoclonales de alta afinidad contra receptores de las DC, con las que pueden desarrollarse vacunas para los seres humanos sobre la base del direccionamiento hacia las DC. Los resultados de los estudios que se describen en la presente reflejan que las vacunas que comprenden antígenos de la tuberculosis pueden evocar una respuesta potente de memoria con especificidad por los antígenos en las células T, que da como resultado la secreción de IFNg.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161466292P | 2011-03-22 | 2011-03-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR085538A1 true AR085538A1 (es) | 2013-10-09 |
Family
ID=46877533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120100964A AR085538A1 (es) | 2011-03-22 | 2012-03-22 | Vacunas para la tuberculosis (tb) basadas en el direccionamiento hacia las celulas dendriticas (dc) |
Country Status (6)
Country | Link |
---|---|
US (1) | US20120244155A1 (es) |
EP (1) | EP2688591A4 (es) |
AR (1) | AR085538A1 (es) |
CA (1) | CA2830987A1 (es) |
TW (1) | TW201305193A (es) |
WO (1) | WO2012129227A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑 |
CN101820910B (zh) * | 2007-05-03 | 2014-08-06 | 新加坡科技研究局 | 结合细胞内prl-1多肽或prl-3多肽的抗体 |
CN103415534A (zh) | 2009-03-10 | 2013-11-27 | 贝勒研究院 | 靶向抗原呈递细胞的癌症疫苗 |
BRPI1009455A2 (pt) | 2009-03-10 | 2016-03-01 | Baylor Res Inst | anticorpos anti-c40 e usos dos mesmos |
JP6566941B2 (ja) | 2013-06-28 | 2019-08-28 | ベイラー リサーチ インスティテュートBaylor Research Institute | 多発性硬化症のための樹状細胞asgpr標的化免疫治療薬 |
WO2015104380A1 (en) * | 2014-01-09 | 2015-07-16 | Transgene Sa | Fusion of heterooligomeric mycobacterial antigens |
EP3992210A1 (en) | 2014-01-13 | 2022-05-04 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
EP3142691A4 (en) | 2014-05-16 | 2018-04-11 | Baylor Research Institute | Methods and compositions for treating autoimmune and inflammatory conditions |
KR20170010863A (ko) | 2014-07-01 | 2017-02-01 | 화이자 인코포레이티드 | 이중특이성 이종이량체성 디아바디 및 이의 용도 |
JP6534146B2 (ja) * | 2015-06-10 | 2019-06-26 | 国立大学法人 東京大学 | ワクチン用アジュバント、ワクチン、及び免疫誘導方法 |
TWI752012B (zh) | 2016-03-04 | 2022-01-11 | 美商Jn生物科學有限責任公司 | 針對tigit之抗體 |
KR101828044B1 (ko) * | 2017-01-18 | 2018-02-09 | 연세대학교 산학협력단 | 수지상 세포 및 항생제를 포함하는 결핵 예방 또는 치료용 조성물 |
KR101892598B1 (ko) * | 2017-01-18 | 2018-08-28 | 연세대학교 산학협력단 | 수지상 세포를 포함하는 결핵 백신 부스터용 조성물 |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
CN109679908B (zh) * | 2019-02-25 | 2020-04-21 | 上海尚泰生物技术有限公司 | 一种制备高纯度人树突状细胞的方法及其应用 |
AU2020253621A1 (en) * | 2019-04-05 | 2021-11-11 | Dren Bio, Inc. | Methods of depleting disease causing agents via antibody targeted phagocytosis |
AU2021284273A1 (en) | 2020-06-02 | 2022-12-15 | Arcus Biosciences, Inc. | Antibodies to TIGIT |
KR20230104617A (ko) | 2020-10-07 | 2023-07-10 | 드렌 바이오, 인크. | 항-덱틴-1 항체 및 이의 사용 방법 |
CN112119977B (zh) * | 2020-10-15 | 2021-10-19 | 中国人民解放军军事科学院军事医学研究院 | Cd317诱导的抑郁和记忆损伤的小鼠模型的构建方法及其应用 |
WO2024160956A1 (en) | 2023-02-02 | 2024-08-08 | Institut National de la Santé et de la Recherche Médicale | Anti-tuberculosis vaccine targeting selected mycobacterium tuberculosis protective antigens to dendritic cells |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7037510B2 (en) * | 1997-04-18 | 2006-05-02 | Statens Serum Institut | Hybrids of M. tuberculosis antigens |
US20020025315A1 (en) * | 1998-01-14 | 2002-02-28 | Naveen N. Anand | Chimeric antibodies for delivery of antigens to selected cells of the immune system |
US20040146948A1 (en) * | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
TWI422594B (zh) * | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑 |
CN103415534A (zh) * | 2009-03-10 | 2013-11-27 | 贝勒研究院 | 靶向抗原呈递细胞的癌症疫苗 |
JP2013504599A (ja) * | 2009-09-14 | 2013-02-07 | ベイラー リサーチ インスティテュート | ランゲルハンス細胞に向けられたワクチン |
EP2566518A4 (en) * | 2010-05-07 | 2013-12-25 | Baylor Res Inst | THROUGH DENDRITIC CELL IMMUNE RECEPTORS MEDIATED CROSS-PRIMING OF HUMAN CD8 + T CELLS |
-
2012
- 2012-03-20 WO PCT/US2012/029802 patent/WO2012129227A1/en active Application Filing
- 2012-03-20 EP EP12760466.8A patent/EP2688591A4/en not_active Withdrawn
- 2012-03-20 CA CA2830987A patent/CA2830987A1/en not_active Abandoned
- 2012-03-20 US US13/424,582 patent/US20120244155A1/en not_active Abandoned
- 2012-03-22 TW TW101109957A patent/TW201305193A/zh unknown
- 2012-03-22 AR ARP120100964A patent/AR085538A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2688591A4 (en) | 2014-10-01 |
CA2830987A1 (en) | 2012-09-27 |
TW201305193A (zh) | 2013-02-01 |
US20120244155A1 (en) | 2012-09-27 |
EP2688591A1 (en) | 2014-01-29 |
WO2012129227A1 (en) | 2012-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR085538A1 (es) | Vacunas para la tuberculosis (tb) basadas en el direccionamiento hacia las celulas dendriticas (dc) | |
CY1120976T1 (el) | Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρων | |
AR076106A1 (es) | Anticuerpos anti-cd40 y usos de los mismos | |
PH12015500977A1 (en) | Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates | |
AR101455A1 (es) | Molécula portadora | |
AR076107A1 (es) | Vacunas anti-virales dirigidas contra celulas presentadoras de antigenos | |
CL2019002036A1 (es) | Anticuerpo contra bcma y su uso. | |
BR112015010436A2 (pt) | Anticorpos anti-notch3 e conjugados anticorpo-fármaco | |
CL2011003091A1 (es) | Composicion que comprende conjugado covalente entre hemoglobina funcional y nativa y al menos una molecula de polietilenglicol; metodo para preparar composicion; uso de dicha composicion para producir medicina de transfusion. | |
CO6771458A2 (es) | Conjugados de anticuerpo-fármaco | |
CL2015001900A1 (es) | Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina. | |
CO7160026A2 (es) | Vacuna contra mycoplasma hyopneumoniae | |
CY1115091T1 (el) | Διειδικες πρωτεϊνες προσδεσης αντιγονων | |
AR091961A1 (es) | Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b) | |
PA8718601A1 (es) | Anticuerpos anti-5t4 y sus usos | |
MX354924B (es) | Molecula portadora que comprende un antigeno spr0096 y un spr2021. | |
AR075851A1 (es) | Vacunas anti-cancer dirigidas contra celulas presentadoras de antigenos | |
CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
CL2012003299A1 (es) | Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma. | |
AR092896A1 (es) | Composiciones inmunogenicas | |
BR112015016817A8 (pt) | métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica | |
AR094919A1 (es) | Usos terapéuticos para anticuerpos vegfr1 | |
AR096123A1 (es) | Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coagulación | |
AR088220A1 (es) | Activacion de celulas dendriticas humanas por el receptor de dectina-1 o de tipo toll 2 (tlr2) en el control de la alergia y el asma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |